Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLG and PTCy for GVHD Prevention in MDS/AML
NCT03357159Phase 2Unknown
- Sponsor
- Sheba Medical Center
- Start
- Sep 2018
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of grafalon in graft-versus-host disease (GVHD), sponsored by Sheba Medical Center. Status: unknown.
02
Drugs
grafalon
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03357159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03357159.